pneumonia

25 September, 2024

HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL

2024-10-18T12:27:27+03:00By hiss|Categories: Biomarkers, Multicenter studies in Greece, Publications|Tags: COVID-19, heparin-binding protein, mortality, pneumonia|

Evdoxia Kyriazopoulou , George N Dalekos, Symeon Metallidis, Garyphalia Poulakou, Ilias C Papanikolaou, Vasiliki Tzavara, Katerina Argyraki, Zoi Alexiou, Periklis Panagopoulos, Michael Samarkos, George Chrysos, Aikaterini Tseliou, Haralampos Milionis, Styliani Sympardi, Anil Vasishta, Evangelos J. Giamarellos-Bourboulis Shock 2024 Mar 1;61(3):395-399. DOI: 10.1097/SHK.0000000000002315View article 🡆 Funding This study was supported in part

4 January, 2024

Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

2024-04-01T11:51:43+03:00By hiss|Categories: Multicenter studies in Greece, Publications, Therapeutics|Tags: clarithromycin, clinical trial, pneumonia|

Evangelos J. Giamarellos-Bourboulis, Athanasios Siampanos, Amalia Bolanou, Sarantia Doulou, Nikolaos Kakavoulis, Konstantinos Tsiakos, Sokratis Katopodis, Georgios Schinas, Lamprini Skorda, Zoi Alexiou, Konstantinos Armenis, Paraskevi Katsaounou, George Chrysos, Aikaterini Masgala, Garyphalia Poulakou, Nikolaos Antonakos, Asimina Safarika, Miltiades Kyprianou, Konstantina Dakou, Styliani Gerakari, Ilias C Papanikolaou, Prof Haralampos Milionis, Prof Markos Marangos, Prof George N Dalekos,

10 October, 2022

INSPIRE

2024-11-04T11:14:45+03:00By hiss|Categories: Interventional, Ongoing, Sepsis and severe infections, Studies|Tags: Anakinra, pneumonia|

Ongoing study Official Study Title Immunotherapy Navigated by Serum Presepsin for Infections of the REspiratory tract: the INSPIRE double-blind, randomized, phase IIa exploratory trial Brief Description The INSPIRE study is an exploratory, randomised, phase IIa clinical trial which aims to evaluate the potential benefit of presepsin-guided anakinra therapy as an adjuvant to the standard

1 September, 2021

The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece

2024-04-02T18:01:32+03:00By hiss|Categories: Publications, Therapeutics|Tags: clarithromycin, COVID-19, pneumonia|

Evangelos J. Giamarellos-Bourboulis, George L Daikos, Panagiotis Gargalianos, Charalambos Gogos, Marios Lazanas, Periklis Panagopoulos, Garyphallia Poulakou, Helen Sambatakou, Michael Samarkos Infectious Diseases and Therapy 2021 Sep;10(3):1081-1095 DOI: 10.1007/s40121-021-00471-1Download pdf 🡇 Funding The study was funded by the Hellenic Institute for the Study of Sepsis. No Rapid Service Fee was received by the

1 January, 2021

ACCESS

2024-02-07T15:52:51+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, pneumonia|

Completed study Official Study Title A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS Brief Description Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to

1 January, 2020

Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study

2023-02-16T14:31:00+03:00By hiss|Categories: Publications, Therapeutics|Tags: azithromycin, clarithromycin, pneumonia|

Evdoxia Kyriazopoulou, Dimitrios Sinapidis, Stamatios Halvatzis, Dimitrios Velissaris, Nikolaos Alexiou, Vasilios Kosmas, Maria-Evangelia Adami, Miltiades Kyprianou, Aikaterini Kyprianou, Aggelos Stefos, Malvina Lada, Pantelis Koutoukas, Maria Pavlaki, Anna Kyriakoudi, Anna Makina, Charalambos Gogos, Michael S Niederman, Evangelos J. Giamarellos-Bourboulis International Journal of Antimicrobial Agents 2020 Jan;55(1):105836 DOI: 10.1016/j.ijantimicag.2019.10.017View article 🡇 Funding The works were